Roche reports a good start in 2017
(WorldNews Switzerland)

Basel, 27 April 2017 Roche reports a good start in 2017 Group sales increase 4% at constant exchange rates and in Swiss francs Pharmaceuticals Division sales up 3%, driven mainly by Tecentriq and Perjeta Diagnostics Division sales grow 6%, primarily due to immunodiagnostic solutions US FDA approves Ocrevus to treat two forms of multiple sclerosis EU approves Alecensa for the treatment of a specific form of lung cancer Successful phase III Aphinity study of Perjeta treatment regimen in early breast cancer Outlook for 2017 confirmed Commenting on the Group`s results, Roche CEO Severin Schwan said: «We have started the year with good growth in both our Pharmaceuticals and Diagnostics Divisions...